米托蒽醌、威猛治疗难治性NHL8例临床报告

Treatment of Refractory Malignant non-Hodgkin Lymphonas (NHL) with Mitoxantrone and Teniposide(VM-26)

难治性、复发性淋巴瘤的治疗是临床肿瘤治疗中的一个棘手问题.本文报告用米托蒽醌、威猛联合治疗难治性NHL8例,其中高度恶性7例,中度恶住1例;男5例,女3例;临床分期:Ⅲ期6例、N期2例、疗效评价;PR6例,S、P各1例,有效率75.0%(6/8).消化道毒性较少发生,多为轻度,患者均能耐受.主要毒性反应为骨髓抑制,Ⅲ-Ⅳ度白细胞减少75. 0%,如能合并使用骨髓刺激因子,可望进一步提高疗效.

Eight patients with relapsing or refractory high or middle-grade malignant non-Hodgkins Lymphoma(NHL) received a combination of mitoxantrone and teniposide (VM-26) were studied PR was oblained in 6(75. 0%)Pts S in I(12. 5%);P in 1 (12. 5%)patient. The dose limiting toxicity is myelosuppression.